View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
April 22, 2021

Coronavirus company news summary – Bharat reports Covaxin efficacy of 78% against symptomatic Covid-19 – Roche to move AT-527 trials out of UK over lack of patients

By Chris Lo

Bharat Biotech has reported results from the Phase III interim analysis of its Covid-19 vaccine candidate, Covaxin. Due to a recent surge in infections, about 127 symptomatic cases were reported, with the interim results suggesting a vaccine efficacy of 78% against symptomatic Covid-19. The analysis also demonstrated 100% efficacy against severe Covid-19, while 70% efficacy was recorded against asymptomatic cases.

Swiss pharma giant Roche will relocate its trials of AT-527, its oral drug candidate to treat Covid-19, as infections dropped in the UK, meaning there are fewer patients needed for the testing. Roche and Atea Pharmaceuticals, which have together developed the AT-527 pill, are hoping it will work as an easier and cheaper antiviral therapy when compared to antibody treatments or Gilead’s remdesivir.

Panama is set to buy two million additional doses of the Pfizer-BioNTech Covid-19 vaccine, expanding its total orders of the vaccine to seven million doses. The central American nation has already received about 600,000 doses of the vaccine. The additional doses will bring its vaccines portfolio to nine million doses, which is expected to be sufficient for almost 90% of the population.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology